Search results
Results From The WOW.Com Content Network
However, the rising dividend yield seems to be just a byproduct of the market selling Pfizer stock off for its declining sales. Management even raised guidance in Q1. Management even raised ...
Image source: Getty Images. 1. AbbVie. AbbVie (NYSE: ABBV) is recognized as a global leader in biopharmaceuticals. The company's portfolio spans multiple therapeutic areas, including its strong ...
Image source: Getty Images. Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% dividend yield-- the highest among major drug ...
A high-yield dividend stock with long-term potential Pfizer's current 5.73% dividend yield stands well above the S&P 500 average of 1.35%. The company's payout ratio of 443% appears unsustainable ...
The good news on this front, though, is that Pfizer is poised to improve its bottom line and make its dividend even safer. Sure, the big pharma company's earnings fell 11% year over year in Q2.
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns. The Best Pharmaceutical Stock to Invest $1,000 in Right Now Skip to main content
With a lot of new drugs to sell, Pfizer expects adjusted earnings to reach a range between $2.15 and $2.35 per share this year, which is more than it needs to meet a dividend commitment currently ...
When it comes to investing in high-yield dividend stocks in the pharmaceutical space, two prominent names often come to mind: Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY).